KRAS and colorectal carcinoma: For instance, microsatellite instability-high (MSI-H) CRC patients achieved better responses toward immune checkpoint inhibitor therapy (5), and KRAS mutations were a negative predictor of response to panitumumab or cetuximab therapies, which both are first-line treatments of CRC (6).